106167-47-9

Upstream product

• 64-17-5 ethanol 
• 41712-14-5 indene-2-carboxylic acid 
• 13070-90-1 ethyl 2-hydroxy-2,3-dihydro-1H-indene-2-carboxylate 
• 98516-80-4 ethyl 2-formyl-3-phenylpropionate 
• 75-03-6 ethyl iodide 
• 55589-21-4 2-hydroxy-indan-2-carbonitrile 
• 2021-28-5 ethyl dihydrocinnamate 
• 6742-25-2 1-oxoindane-2-carboxylic acid ethyl ester 
• 6630-33-7 ortho-bromobenzaldehyde 
• 140-88-5 ethyl acrylate 
• 86867-62-1 (E)-3-(2-formylphenyl)propenoic acid ethyl ester 
• 95-13-6 1-indene 
• 43073-37-6 1H-indene-2-carbonyl chloride 
• 37442-45-8 ethyl 2-(hydroxy(phenyl)methyl)propenoate 

Downstream Products

• 214605-44-4 (1S,2R)-1-Azido-2-benzoyloxy-indan-2-carboxylic acid ethyl ester 
• 343868-86-0 (1S,2R)-ethyl 1-bromo-2-benzoyloxyindan-2-carboxylate 
• 343868-81-5 (1R,2S)-ethyl 1-bromo-2-benzoyloxyindan-2-carboxylate 
• 343868-87-1 (1R,2S)-ethyl 1-benzoylamino-2-hydroxyindan-2-carboxylate 
• 343868-82-6 (1S,2R)-ethyl 1-benzoylamino-2-hydroxyindan-2-carboxylate 

Relevant academic research and scientific papers

Cyclopentadienyl molybdenum(II) compounds bearing carboxylic acid functional group

This work describes a procedure giving cyclopentadienyl molybdenum(II) compounds bearing carboxylic acid function group. It involves synthesis of carboxylic acid ester functionalized cyclopentadienides, their coordination to molybdenum(II) precursor and saponification of ester function groups. The method is not limited only to compounds with the function group directly attached in the cyclopentadienyl ring but also to those functionalized in the side chain. The attempts to synthesize the indenyl analogues were only partially successful due to low stability in the saponification step. All reported structure types were elucidated from spectroscopic measurements and verified by X-ray crystallography. The second part of the work describes an effect of the outer-coordination sphere on cytotoxicity of the cationic molybdenum(II) compounds bearing N,N-chelating ligands. The cytotoxicity of the modified species bearing phenanthroline ligand toward human leukemia cells MOLT-4 (IC50 = 10.5 ± 0.5 μmol l?1) is higher than reported for cisplatin (IC50 = 15.8 ± 1.9 μmol l?1).

From isonitrile to nitrile via ketenimine intermediate: Palladium-catalyzed 1,1-carbocyanation of allyl carbonate by α-isocyanoacetate

A palladium-catalyzed 1,1-carbocyanation of allyl carbonate by α-quaternary α-isocyanoacetate was developed. Formation of ketenimine followed by homolysis of the C–N bond and recombination of the resulting caged radical pair was proposed to account for the formation of the unusual coupling product, the β-cyano-γ,δ-unsaturated ester.

Facile and innovative catalytic protocol for intramolecular Friedel-Crafts cyclization of Morita-Baylis-Hillman adducts: Synergistic combination of chiral (salen)chromium(III)/ BF3 OEt2 catalysis

The chiral (salen)Cr(III)/BF3 OEt2 catalytic combination was found to be an effective catalyst for intramolecular Friedel-Crafts cyclization of electron-deficient Morita-Baylis-Hillman adducts. In presence of mild reaction conditions the chiral (salen)Cr(

CoIII-Carbene Radical Approach to Substituted 1H-Indenes

A new strategy for the catalytic synthesis of substituted 1H-indenes via metalloradical activation of o-cinnamyl N-tosyl hydrazones is presented, taking advantage of the intrinsic reactivity of a CoIII carbene radical intermediate. The reaction uses readily available starting materials and is operationally simple, thus representing a practical method for the construction of functionalized 1H-indene derivatives. The cheap and easy to prepare low spin cobalt(II) complex [CoII(MeTAA)] (MeTAA = tetramethyltetraaza[14]annulene) proved to be the most active catalyst among those investigated, which demonstrates catalytic carbene radical reactivity for a nonporphyrin cobalt(II) complex, and for the first time catalytic activity of [CoII(MeTAA)] in general. The methodology has been successfully applied to a broad range of substrates, producing 1H-indenes in good to excellent yields. The metallo-radical catalyzed indene synthesis in this paper represents a unique example of a net (formal) intramolecular carbene insertion reaction into a vinylic C(sp2)-H bond, made possible by a controlled radical ring-closure process of the carbene radical intermediate involved. The mechanism was investigated computationally, and the results were confirmed by a series of supporting experimental reactions. Density functional theory calculations reveal a stepwise process involving activation of the diazo compound leading to formation of a CoIII-carbene radical, followed by radical ring-closure to produce an indanyl/benzyl radical intermediate. Subsequent indene product elimination involving a 1,2-hydrogen transfer step regenerates the catalyst. Trapping experiments using 2,2,6,6-tetra-methylpiperidine-1-oxyl (TEMPO) radical or dibenzoylperoxide (DBPO) confirm the involvement of cobalt(III) carbene radical intermediates. Electron paramagnetic resonance spectroscopic spin-trapping experiments using phenyl N-tert-butylnitrone (PBN) reveal the radical nature of the reaction.

Reactions and mechanistic studies of rhenium-catalyzed insertion of α,β-unsaturated carbonyl compounds into a C-H bond

A rhenium complex, [ReBr(CO)3(thf)]2, catalyzes the insertion of α, β-unsaturated carbonyl compounds into a C-H bond of aromatic compounds having nitrogen-containing directing groups. In this reaction, Re2(CO)10 can also be used as a catalyst. When imines are employed as the aromatic substrates, sequential cyclization proceeds and indene derivatives are obtained in good to excellent yields. This reactivity is in contrast to those of ruthenium and rhodium complexes, which are usually used as catalysts in the insertion reactions of unsaturated molecules into a C-H bond. Investigations on the reaction mechanism indicate that the rhenium catalyst promotes C-H bond activation of aromatic compounds, the insertion of α, β-unsaturated carbonyl compounds into a Re-C bond, and intramolecular nucleophilic cyclization followed by reductive elimination and the elimination of an amine.

Inter- and intramolecular palladium-catalyzed allyl cross-coupling reactions using allylindium generated in situ from allyl acetates, indium, and indium trichloride

Inter- and intramolecular palladium-catalyzed ally! cross-coupling reactions using allylindium generated in situ by treatment of allyl acetates with indium and indium trichloride in the presence of Pd0 catalyst and nBuNMe2 in DMF were successfully demonstrated. Allylindium species generated in situ by reductive transmetalation of π- allylpalladium(II) complexes, obtained from a variety of allyl acetales in the presence of Pd0 catalyst together with indium and indium trichloride, were found to be capable of acting as effective nucleophilic coupling partners in Pd-catalyzed cross-coupling reactions. A variety of allyl acetates such as but-l-en-3-yl acetate, crotyl acetate, and 2-methylallyl acetate afforded the corresponding allylic compounds in good yields in cross-coupling reactions. Various electrophilic cross-coupling partners such as aryl iodides and vinyl bromides and triflates participate in these reactions. Not only intermolecular but also intramolecular Pd-catalyzed cross-coupling reactions work equally well to produce the desired allylic coupling products in good yields.

Antiarrythmic and cardioprotective substituted indenoylguanidines

Indenoylguanidines of formula I and formula II, the process for their preparation, their use as medicaments, medicaments containing them, their use as diagnostic agents and medicaments containing them are described. Compounds I are useful for treating cardiac arrhythmias. Further they are useful as cardioprotective agents in mammals, which comprises administering the compound of formula-I or II with the above properties in combination with pharmaceutically accepted carrier to said mammal. STR1

Anti-arrhythmic and cardioprotective substituted indenoylguanidines

Indenoylguanidines of formula I, the process for their preparation, their use as medicaments, medicaments containing them, their use as diagnostic agents and medicaments containing them are described. Compounds I are useful for treating cardiac arrhythmias. Further they are useful as cardioprotective agents in mammals, which comprises administering the compound of formula-I with the above properties in combination with pharmaceutically accepted carrier to said mammal.